Effects of enzymatically depolymerised fucoidan on effector functions of innate and adaptive immunity cells

The use of sulfated polysaccharides (fucoidans) as active pharmaceutical ingredients or adjuvants poses the challenge of obtaining structurally characterised and homogeneous samples or their oligomeric fractions maintaining high biological activity. The authors obtained a highly purified enzymatic hydrolysate of fucoidan from the brown alga Fucus evanescens and compared its biological activity with that of a native sample. The aim of the study was to compare, in vitro and in vivo, the effects of depolymerised fucoidan from the brown alga F. evanescens and native fucoidan on the effector functions of innate and adaptive immunity cells loaded with ovalbumin (OVA). Materials and methods: the effects of the fucoidan samples (depolymerised and native) on the expression of the main immunophenotypic markers by innate and adaptive immunity cells (neutrophils, monocytes, natural killers, and lymphocytes) were studied in vitro using flow cytometry. The levels of serum OVA-specific antibodies (IgG, IgG1, IgG2а) and cytokines (IFN-γ, IL-2, IL-10, IL-12) were studied in vivo using BALB/c mice immunised with OVA. The statistical analysis of the data obtained was performed using the Statistica 10 software package. Results: in vitro, both fucoidan samples altered the expression of the main immunophenotypic markers by innate and adaptive immunity cells, indicating their activation. In vivo, mice treated with the fucoidan samples demonstrated an increase in the levels of OVA-specific antibodies (IgG, IgG1 and IgG2a) and in the production of cytokines (IFN-γ, IL-2, IL-10). Conclusions: the effects of enzymatically depolymerised fucoidan on functional activity of innate and adaptive immunity cells are comparable to those of native fucoidan. The findings indicate the possibility of using enzymatic hydrolysis products of fucoidan as adjuvants for a wide range of prophylactic and therapeutic vaccines.

1. Menshova RV, Shevchenko NM, Imbs TI, Zvyagintseva TN, Malyarenko OS, Zaporoshets TS, et al. Fucoidans from Brown Alga Fucus evanescens: structure and biological activity. Front Marine Sci. 2016;3:1–9. https://doi.org/10.3389/fmars.2016.00129

2. Silchenko AS, Rasin AB, Kusaykin MI, Malyarenko OS, Shevchenko NM, Zueva AO, et al. Modification of native fucoidan from Fucus evanescens by recombinant fucoidanase from marine bacteria Formosa algae. Carbohydr Polym. 2018;193:189–95. https://doi.org/10.1016/j.carbpol.2018.03.094

3. Anastyuk SD, Shevchenko NM, Dmitrenok PS, Zvyagintseva TN. Structural similarities of fucoidans from brown algae Silvetia babingtonii and Fucus evanescens, determined by tandem MALDI-TOF mass spectrometry. Carbohydr Res. 2012;358:78–81. https://doi.org/10.1016/j.carres.2012.06.015

4. Dubois M, Gilles K, Hamilton JK, Rebers PA, Smith F. A colorimetric method for the determination of sugars. Nature. 1951;168(4265):167. https://doi.org/10.1038/168167a0

5. Dodgson KS, Price RG. A note on the determination of the ester sulphate content of sulphated polysaccharides. Biochem J. 1962;84(1):106–10. https://doi.org/10.1042/bj0840106

6. Waffenschmidt S, Jaenicke L. Assay of reducing sugars in nanomole range with 2,2-bicinchoninate. Anal Biochem. 1987;165(2):337–40. https://doi.org/10.1016/0003-2697(87)90278-8

7. Romee R, Foley B, Lenvik T, Wang Y, Zhang B, Ankarlo D, et al. NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17). Blood. 2013;121(18):3599–608. https://doi.org/10.1182/blood-2012-04-425397

8. Ahmad F, Tufa DM, Mishra N, Jacobs R, Schmidt RE. Terminal differentiation of CD56(dim)CD16(+) natural killer cells is associated with increase in natural killer cell frequencies after antiretroviral treatment in HIV-1 infection. AIDS Res Hum Retroviruses. 2015;31(12):1206–12. https://doi.org/10.1089/aid.2015.0115

9. Kuznetsova TA, Persiyanova EV, Ermakova SP, Khotimchenko MYu, Besednova NN. The sulfated polysaccharides of Brown Algae and products of their enzymatic transformation as potential vaccine adjuvants. Nat Prod Com. 2018;13(8);1083–95. https://doi.org/10.1177/1934578X1801300837

10. Zhang W, Oda T, Yu Q, Jin JO. Fucoidan from Macrocystis pyrifera has powerful immune-modulatory effects compared to three other fucoidans. Mar Drugs. 2015;13(3):1084–104. https://doi.org/10.3390/md13031084

11. Kim SY, Joo HG. Evaluation of adjuvant effects of fucoidan for improving vaccine efficacy. J Vet Sci. 2015;16(2):145–50. https://doi.org/10.4142/jvs.2015.16.2.145

12. Ikewaki N, Dedeepiya VD, Raghavan K, Rao KS, Vaddi S, Osawa H, et al. β-glucan vaccine adjuvant approach for cancer treatment through immune enhancement (B–VACCIEN) in specific immunocompromised populations (Review). Oncol Rep. 2022;47(1):14. https://doi.org/10.3892/or.2021.8225

13. Pifferi C, Fuentes R, Fernández-Tejada A. Natural and synthetic carbohydrate-based vaccine adjuvants and their mechanisms of action. Nat Rev Chem. 2021;5(3):197–216. https://doi.org/10.1038/s41570020-00244-3

14. Seder RA, Hill AV. Vaccines against intracellular infections requiring cellular immunity. Nature. 2000;406(6797):793–8. https://doi.org/10.1038/35021239

15. McKee AS, Munks MW, Marrack P. How do adjuvants work? Important considerations for new generation adjuvants. Immunity. 2007;27(5):687–90. https://doi.org/10.1016/j.immuni.2007.11.003

16. Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity. 2010;33(4):492–503. https://doi.org/10.1016/j.immuni.2010.10.002

17. Mathers AR, Cuff CF. Role of interleukin-4 (IL-4) and IL-10 in serum immunoglobulin G antibody responses following mucosal or systemic reovirus infection. J Virol. 2004;78(7):3352–60. https://doi.org/10.1128/jvi.78.7.3352-3360.2004

18. Gherardi RK, Eidi H, Crépeaux G, Authier FJ, Cadusseau J. Biopersistence and brain translocation of aluminum adjuvants of vaccines. Front Neurol. 2015;6:4. https://doi.org/10.3389/fneur.2015.00004